Shock Wave Therapy for Peyronie's Disease
Shock wave therapy (ESWT) should NOT be used to treat the primary manifestations of Peyronie's disease—it does not reduce penile curvature or plaque size, which are the clinically meaningful outcomes that impact quality of life and sexual function. 1, 2
Primary Recommendation: Do Not Use ESWT for Curvature or Plaque
The most recent 2025 European Association of Urology guidelines and the 2015 American Urological Association guidelines both explicitly state that ESWT should not be used for reducing penile curvature or plaque size. 1, 2
Why ESWT Fails for Meaningful Outcomes:
No curvature improvement: Multiple randomized controlled trials demonstrate that curvature reduction is similar between ESWT and placebo/sham treatment groups, with some studies showing curvature actually worsened in 40% of ESWT patients versus 24.5% in placebo groups 2, 3
No plaque reduction: RCTs consistently show no meaningful effect on plaque size, with some evidence of plaque size increasing in ESWT-treated patients 2, 3
No erectile function benefit: Studies fail to demonstrate improvement in International Index of Erectile Function scores 1, 4
The Evidence Contradiction You Should Know:
While a 2024 meta-analysis 5 and one 2009 RCT 6 suggested potential plaque reduction, the highest-quality guideline panels reviewed the same evidence and concluded this finding lacks clinical significance 1, 2. The 2021 meta-analysis by Bakr et al. explicitly states "ESWT fails to improve penile curvature or pain" and notes plaque reduction remains "of questionable clinical significance" 4.
Limited Role: Pain Relief Only (With Major Caveats)
ESWT may be offered solely for penile pain relief in the active disease phase, but this represents extremely limited utility. 1, 2
Why This Recommendation Is Weak:
Pain resolves spontaneously: Penile pain in Peyronie's disease typically resolves on its own over time as the disease stabilizes 2, 7
Better alternatives exist: NSAIDs and daily tadalafil 5 mg are effective for pain control without the burden and cost of ESWT 1, 8
Substantial patient burden: ESWT requires multiple weekly sessions (typically 4-6 weeks, one session per week, 2,000-3,000 shock waves per session) 2
Overall utility is low: Even the AUA guidelines that conditionally permit ESWT for pain explicitly state "the overall utility of ESWT in the management of PD is low" 2
What Actually Works: Evidence-Based Alternatives
For Active Disease (Pain-Dominant Phase):
- NSAIDs for pain control 1, 8
- Daily tadalafil 5 mg to reduce curvature progression and improve symptoms 1, 8
For Stable Disease (Curvature-Dominant Phase):
Intralesional collagenase clostridium histolyticum (CCH): Produces mean curvature reduction of approximately 17° versus 9.3° with placebo (Level A evidence) 8, 9
Penile traction therapy: Safe and effective with second-generation devices, requires 2-8 hours daily use 1, 8, 9
Surgical correction: Gold standard for severe or complex deformities in patients with stable disease >3-6 months 1, 8
Critical Clinical Pitfalls to Avoid
Do not offer ESWT simply because patients request "something non-invasive"—this delays definitive treatment during the critical therapeutic window. 8
- ESWT creates false hope while the disease may progress 8
- Curvature can worsen during ESWT treatment 2, 3
- Financial burden is substantial without meaningful benefit 7
- Time wasted on ineffective therapy postpones treatments with proven efficacy 1, 8
The 2025 EAU treatment algorithm includes low-intensity ESWT (LI-ESWT) only as an option for pain control alongside NSAIDs and tadalafil—it is explicitly NOT included in the pathway for treating curvature or plaque. 1